Celgene's psoriasis drug Otezla gets thumbs down from IQWiG
This article was originally published in Scrip
Executive Summary
Celgene has been slapped with a poor benefit rating for psoriasis drug Otezla (apremilast) in Germany after failing to submit necessary data comparing the drug to other available therapies.